Clinical Pharmacology and Therapeutics 1991: Vol 50 Index

19 Pages·1991·4.8 MB·English

LINICAL
HARMACOLOGY
& THERAPEUTICS
EDITOR Milo Gibaldi, PhD
Marcus M. Reidenberg, MD Peter Goldman, MD
Jean Gray, MD, FRCP(C)
FOUNDING EDITOR Linda E. Gustavson, PhD
Walter Modell, MD Perry V. Halushka, MD, PhD
Arthur Hull Hayes, Jr., MD
Thomas K. Henthorn, MD
ASSOCIATE EDITORS
Peter H. Hinderling, MD
Arthur J. Atkinson, Jr., MD
Jordan L. Holtzman, MD, PhD
Paul D. Stolley, MD, MPH
Aryeh Hurwitz, MD
Raymond L. Woosley, MD, PhD
Harold D. Itskovitz, MD
Patrice Jaillon, MD
ASSISTANT EDITOR
William J. Jusko, PhD
B. Robert Meyer, MD Anthony Kales, MD
Stanley A. Kaplan, PhD
MANAGING EDITOR Louis Lemberger, PhD, MD
June Reidenberg Juan J. L. Lertora, MD, PhD
Gerhard Levy, PharmD
EDITORIAL BOARD David T. Lowenthal, MD, PhD
Darrell R. Abernethy, MD, PhD Carl V. Manion, MD
Alvito P. Alvares, PhD Urs A. Meyer, MD
Matthew M. Ames, PhD Jerry R. Mitchell, MD, PhD
Fred Y. Aoki, MD Edward B. Nelson, MD, PhD
Daniel L. Azarnoff, MD Harold C. Neu, MD
William M. Bennett, MD David W. Nierenberg, MD
Leif Bertilsson, PhD Alan S. Nies, MD
Joseph R. Bianchine, MD, PhD George D. Olsen, MD
Thorir D. Bjornsson, MD Carl C. Peck, MD
Terrence F. Blaschke, MD William Z. Potter, MD, PhD
Saul S. Bloomfield, MD David Robertson, MD
Paula Botstein, MD Jerome J. Schentag, PharmD
R. A. Branch, MD Edward M. Sellers, MD, PhD, FRCP(C)
D. Craig Brater, MD Lewis B. Sheiner, MD
Alastair Breckenridge, MSc, MD Daniel S. Sitar, PhD
Edward A. Carr, Jr., MD Folke Sjoqvist, MD
S. George Carruthers, MD Cedric M. Smith, MD
David M. Cocchetto, PhD Reynold Spector, MD
Robert J. Cody, Jr., MD Stephen P. Spielberg, MD, PhD, FRCP(C)
Allan H. Conney, PhD Donald R. Stanski, MD
Joann L. Data, MD, PhD Robert Temple, MD
Colin Dollery, MB, ChB, BSc Elliot S. Vesell, MD
Edward F. Domino, MD Robert E. Vestal, MD
Dennis E. Drayer, PhD Miles M. Weinberger, MD
Akio Ebihara, MD Richard Weinshilboum, MD
David J. Edwards, PharmD William B. White, MD
Toby R. Engel, MD Thomas L. Whitsett, MD
William E. Evans, PharmD Grant R. Wilkinson, PhD
Alvan R. Feinstein, MD Alastair J. J. Wood, MB, ChB
Kathleen Giacomini, PhD
VOLUME 50, JULY-DECEMBER 1991
MOSBY-YEAR BOOK, INC., ST. LOUIS
Volume 50
Copyright © 1991 by
Mos-b—Y eya r Book, Inc.
All rights reserved
Printed in the United States of America
Index to volume 50
Author index
A Benowitz NL, Chan K, Denaro CP, Jacob PI II. Stable isotope
Aalto-Setala K, Kontula K, Manttari M, Huttunen J, Manninen method for studying transdermal drug absorption: the
V, Koskinen P, Frick HM. DNA polymorphisms of nicotine patch. 1991;50:286-93
apolipoprotein B and AIJ/CIII genes and response to ——, Jacob P III. Nicotine metabolism in humans.
1991;50:462 (Letter)
gemfibrozil treatment. 1991;50:208-14
Abernethy DR. A message from the president. 1991;50:114 Berezin F (see Ratain et al). 1991;50:573-9
. A message from the president—come to Orlando, Berridge MS (see Bednarczyk et al). 1991;50:165-71
March 18-20, 1992. 1991;50:738 Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz
——.. A practitioner’s point of view. 1991;50:612-3 (Work- M, Kewitz H. Pharmacokinetics of galanthamine in hu-
shop) mans and corresponding cholinesterase inhibition.
1991;50:420-8
Abraham PA (see Halstenson et al). 1991;50:702-12
Abrams WB. Submissions by meeting participants. Bickel WK (see Oliveto et al). 1991;50:157-64
1991;50:639-40 (Workshop) Bird JA (see Lipton and Bird). 1991;50:616-9 (Workshop)
——. Workshop on drug utilization review: introduction. Bixler EO (see Vgontzas et al). 1991;50:730-7
1991;50:593-5 (Workshop) Blaschke TF (see Ford et al). 1991;50:192-8
Adler LP (see Bednarczyk et al). 1991;50:165-71 Borsa-Lebas F (see Humbert et al). 1991;50:682-7
Agrawal KC (see Lertora et al). 1991;50:442-9 Botteron GW (see Hurwitz et al). 1991;50:299-307
Aitken ML (see Hutabarat et al). 1991;50:695-701 Boucher BA, Kuhl DA, Fabian TC, Robertson JT. Effect of
Akintonwa AA (see Mabadeje et al). 1991;50:121-4 (Com- neurotrauma on hepatic drug clearance. 1991;50:487-97
mentary) Bowers LD (see Halikas et al). 1991;50:81-95
Akpan W (see Martin et al). 1991;50:429-36 Branch RA (see Brown et al). 1991;50:363-71
Anderson KE (see Pantuck et al). 1991;50:254-8 Branchaud C (see Bairam et al). 1991;50:32-8
Aranda JV (see Bairam et al). 1991;50:32-8 Brandli DW, Sarkissian E, Ng SC, Paulus HE. Individual vari-
Arbuck SG (see Stewart et al). 1991;50:385-93 ability in concentrations of urinary sulindac sulfide.
Ashorobi RB (see Mabadeje et al). 1991;50:121-4 (Commen- 1991;50:650-5
Brater DC (see Tsao et al). 1991;50:713-20
tary)
Atkinson AJ Jr, Nadzam DM, Schaff RL. An indicator-based Breimer DD (see Schellens et al). 1991;50:520-8
program for improving medication use in acute care hospi- (see Soons et al). 1991;50:394-403
tals. 1991;50:125-8 (Commentary) (see van Steveninck et al). 1991;50:172-80
Brockmiller J (see Rost et al). 1991;50:141-9
B Broder S (see Hartman et al). 1991;50:278-85
Bachus R (see Bickel et al). 1991;50:420-8 Brown A (see Schachtel et al). 1991;50:322-9
Baggott JE (see Morgan et al). 1991;50:547-56 Brown NJ, Ryder D, Branch RA. A pharmacodynamic inter-
Bairam A, Branchaud C, Beharry K, Rex J, Laudignon N, action between caffeine and phenylpropanolamine.
Papageorgiou A, Aranda JV. Doxapram metabolism in 1991;50:363-71
human fetal hepatic organ culture. 1991;50:32-8 Brumpt I (see Humbert et al). 1991;50:682-7
Bakker EN (see Schellens et al). 1991;50:520-8 Brunner HR (see Burnier et al). 1991;50:181-91
Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE. Bryant NR (see DiMasi et al). 1991;50:471-86 (Commentary)
Local forearm vasodilation with intra-arterial administra- Burnier M, Ganslmayer M, Perret F, Porchet M, Kosoglou T,
tion of enalaprilat in humans. 1991;50:314-21 Gould A, Nussberger J, Waeber B, Brunner HR. Effects of
Barbhaiya RH (see Shyu et al). 1991;50:503-7 SCH 34826, an orally active inhibitor of atrial natriuretic
Bares R (see Gladziwa et al). 1991;50:673-81 peptide degradation, in healthy volunteers. 1991;50:181-
Battig K (see Hasenfratz and Battig). 1991;50:456-61 91
Bauer LA (see O’ Sullivan et al). 1991;50:450-5 Burris JF. Dose-comparability of atenolol and betaxolol.
(see Reiss et al). 1991;50:379-84 1991;50:350 (Letter)
Bednarczyk EM, Green JA, Nelson AD, Leisure GA, Little D, Byrne L (see Weintraub et al). 1991;50:330-7
Adler LP, Berridge MS, Panacek EA, Miraldi FD. Com-
Cc
parison of the effect of temafloxacin, ciprofloxacin, or pla-
cebo on cerebral blood flow, glucose, and oxygen Calvert R (see Wolff et al). 1991;50:199-207
metabolism in healthy subjects by means of positron emis- Campbell JN (see Manning et al). 1991;50:721-9
sion tomography. 1991;50:165-71 Carlson GA (see Halikas et al). 1991;50:81-95
Beharry K (see Bairam et al). 1991;50:32-8 Carson JL (see Strom et al). 1991;50:107-13
Carter JG (see Grimsley et al). 1991;50:10-5
Caswell KC (see Hughes et al). 1991;50:538-46
*July, pp. 1-120; August, pp. 121-232; September, pp. 233-356; October, pp.
Chaing DS (see Schachtel et al). 1991;50:322-9
357-470; November (Part 1), pp. 471-592; November (Part 2), pp. 593-640; De-
cember, pp. 641-760 Chan K (see Benowitz et al). 1991;50:286-93
CLIN PHARMACOL THER
746 Author index DECEMBER 1991
Chattopadhyay B (see Kyerematen et al). 1991;50:463~4 (Let- Fattinger K, Vozeh S, Olafsson A, Vicek J, Wenk M, Follath
ter reply) F. Netilmicin in the neonate: population pharmacokinetic
CherrieJ (see Relling et al). 1991;50:308-13 analysis and dosing recommendations. 1991;50:55-65
Christensen ML (see Crom et al). 1991;50:132-40 Feely M (see Wolff et al). 1991;50:199-207
Chung D (see Matsui et al). 1991;50:294-8 Fenwick JW (see Oliveto et al). 1991;50:157-64
Cohen AF (see Koster et al). 1991;50:267-77 Ferencz N (see Lertora et al). 1991;50:442-9
(see Soons et al). 1991;50:394-403 Fertil B (see Laplanche et al). 1991;50:39-54
(see van Steveninck et al). 1991;50:172-80 Fischer JP (see Bickel et al). 1991;50:420-8
Conney AH (see Pantuck et al). 1991;50:254-8 Fleming RA (see Stewart et al). 1991;50:385-93
Crea F (see Halikas et al). 1991;50:81-95 Flora KP (see Hartman et al). 1991;50:278-85
Crom WR, Relling MV, Christensen ML, Rivera GK, Evans Follath F (see Fattinger et al). 1991;50:55-65
WE. Age-related differences in hepatic drug clearance in Ford GA, Katzir D, Blaschke TF, Hoffman BB. Responsive-
children: studies with lorazepam and _ antipyrine. ness of peripheral veins to vasodilators and the effect of
1991;50:132-40 nifedipine on o-adrenergic responsiveness in hypertension.
Crosby RD (see Halikas et al). 1991;50:81-95 1991;50:192-8
Cusson JR (see Quérin et al). 1991;50:437-41 Francom SF (see Hughes et al). 1991;50:538-46
Freeman DJ (see Stern et al). 1991;50:66-70
D
Frick HM (see Aalto-Setala et al). 1991;50:208-14
Dakshinamurty KV (see Gladziwa et al). 1991;50:673-81 Frydman A (see Humbert et al). 1991;50:682-7
Danhof M (see Koopmans et al). 1991;50:16-24 Funck-Brentano C, Jacqz-Aigrain E, Leenhardt A, Roux A,
Data JL. A note from the Scientific Program Committee chair- Poirier JM, Jaillon P. Influence of amiodarone on geneti-
person: submission of abstracts for the 1991 annual meet- cally determined drug metabolism in humans.
ing. 1991;50:115 1991;50:259-66
deBethizy JD (see Kyerematen et al). 1991;50:463-4 (Letter
G
reply)
de Bruin H (see van Heiningen et al). 1991;50:410-9 Ganslmayer M (see Burnier et al). 1991;50:181-91
DeLoof MJ (see Hughes et al). 1991;50:538-46 George WJ (see Lertora et al). 1991;50:442-9
Denaro CP (see Benowitz et al). 1991:50:286-93 Geppert E (see Elliott and Geppert). 1991;50:249-53 (Com-
DeVane CL (see Osman et al). 1991;50:656-62 mentary)
DeVane L (see Kirkwood et al). 1991;50:404-9 Ghabrial H (see Schellens et al). 1991;50:520-8
DiMasi JA, Bryant NR, Lasagna L. New drug development in Ghaly G (see Dundee and Ghaly). 1991;50:78-80
the United States from 1963 to 1990. 1991;50:471-86 Giles TD, Quiroz AC, Roffidal LE, Marder H, Sander GE.
(Commentary) Prolonged hemodynamic benefits from a high-dose bolus
Dingemanse J (see Koopmans et al). 1991;50:16-24 injection of human atrial natriuretic factor in congestive
Disch M (see Nierenberg et al). 1991;50:580-6 heart failure. 1991;50:557-63
D’Mello AP (see Grimsley et al). 1991;50:10-5 Gladziwa U, Bares R, Klotz U, Dakshinamurty KV, Ittel TH,
Dodge WF, Jelliffe RW, Richardson CJ, McCleery RA, Seiler KU, Sieberth HG. Pharmacokinetics and phar maco-
Hokanson JA, Snodgrass WR. Gentamicin population dynamics of cisapride in patients undergoing hemodialysis.
pharmacokinetic models for low birth weight infants using 1991;50:673-81
anew nonparametric method. 1991;50:25-31 Goldberg MR (see Warren et al). 1991;50:71-7
Dollery CT (see Warren et al). 1991;50:71-7 Golik A (see Weintraub et al). 1991;50:330-7
D’Souza MJ (see Grimsley et al). 1991;50:10-5 Gonzalez FJ, Meyer UA. Molecular genetics of the
Dundee JW, Ghaly G. Local anesthesia blocks the antiemetic debrisoquin-sparteine polymorphism. 1991;50:233-8
action of P6 acupuncture. 1991;50:78-80 (Commentary)
Dunkle L (see Shyu et al). 1991;50:503-7 Gould A (see Burnier et al). 1991;50:181-91
Graves NM (see Halikas et al). 1991;50:81-95
E
Green JA (see Bednarczyk et al). 1991;50:165-71
Easterling TR (see Reiss et al). 1991;50:379-84 Greenblatt DJ (see Osman et al). 1991;50:656-62
Edgar B (see Soons et al). 1991;50:394-403 Greene P (see Tsao et al). 1991;50:713-20
Elliott WJ, Geppert E. Development of a successful fourth- Grégoire S (see Quérin et al). 1991;50:437-41
year medical school elective course in therapeutics. Grimsley SR, Jann MW, Carter JG, D’Mello AP, D’Souza MJ.
1991;50:249-53 (Commentary) Increased carbamazepine plasma concentrations after
Erwin WG. The definition of drug utilization review: state- fluoxetine coadministration. 1991;50:10-5
ment of issues. 1991;50:596-9 (Workshop) Grunau V (see Matsui et al). 1991;50:294-8
Evans WE (see Crom et al). 1991;50:132-40 Guerciolini R, Szumlanski C, Weinshilboum RM. Human
(see Relling et al). 1991;50:308-13 liver xanthine oxidase: nature and extent of individual vari-
(see Stewart et al). 1991;50:385-93 ation. 1991;50:663-72
Eve MD (see van Heiningen et al). 1991;50:410-9
H
F
Halikas JA, Crosby RD, Carlson GA, Crea F, Graves NM,
Fabian TC (see Boucher et al). 1991;50:487-97 Bowers LD. Cocaine reduction in unmotivated crack users
VOLUME 50
Author index 747
NUMBER 6
using carbamazepine versus placebo in a short-term, dou- Jonkman JHG (see van Heiningen et al). 1991;50:410-9
ble-blind crossover design. 1991;50:81-95
K
Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe
M, Sobota JT, Abraham PA. Comparative phar macokinet- Kadlec KE (see Naranjo et al). 1991;50:96-106
ics and pharmacodynamics of epoetin alfa and epoetin Kales A (see Vgontzas et al). 1991;50:730-7
beta. 1991;50:702-12 ; . Use of caffeine metabolite ratios to explore
Hartman NR, Yarchoan R, Pluda JM, Thomas RV, Wyvill CYP1A2 and xanthine oxidase activities. 1991;50:508-19
KM, Flora KP, Broder S, Johns DG. Pharmacokinetics of Kalow W, Tang BK. Effects of smoking on urinary metabo-
2’,3’-dideoxyinosine in patients with severe human im- lites. 1991;50:465 (Letter reply)
munodeficiency infection. II. The effects of different oral Kappas A (see Pantuck et al). 1991;50:254-8
formulations and the presence of other medications. Kasper FJ (see Koster et al). i991;50:267-77
1991;50:278-85 Katz SA (see Halstenson et al). 1991;50:702-12
Hasenfratz M, Battig K. Nicotine absorption: subjective and Katzir D (see Ford et al). 1991;50:192-8
physiologic effects of nicotine toothpicks. 1991;50:456-61 Kaufmann B (see Martin et al). 1991;50:429-36
Hay A (see Wolff et al). 1991;50:199-207 Kewitz H (see Bickel et al). 1991;50:420-8
Hayes P (see Kirkwood et al). 1991;50:404-9 Kientsch-Engel R (see Martin et al). 1991;50:429-36
Heifetz SM (see Bank et al). 1991;50:314-21 Kirkwood C, Moore A, Hayes P, DeVane L, Pelonero A. In-
Hekster Y A (see Wymenga et al). 1991;50:215-20 fluence of menstrual cycle and gender on alprazolam phar-
Hermann C (see Matsui et al). 1991;50:294-8 macokinetics. 1991;50:404-9
Higgins ST (see Oliveto et al). 1991;50:157-64 Kivist6 KT (see Neuvonen et al). 1991;50:498-5G2
Hoffman BB (see Ford et al). 1991;50:192-8 Klein J (see Matsui et al). 1991;50:294-8
Hokanson JA (see Dodge et al). 1991;50:25-31 Klotz U (see Gladziwa et al). 1991;50:673-81
Hoop RS (see Shepherd et al). 1991;50:338-49 Kluft C (see Koster et al). 1991;50:267-77
Horn JR (see O’ Sullivan et al). 1991;50:450-5 Knapp DA. Development of criteria for drug utilization re-
(see Reiss et al). 1991;50:379-84 view. 1991;50:600-2 (Workshop)
Horne C (see Schulte et al). 1991;50:372-8 Knupp CA (see Shyu et al). 1991;50:503-7
Horsten GPM (see Koopmans et al). 1991;50:16-24 Konerman JP (see Schachtel et al). 1991;50:322-9
Hughes EM (see Hurwitz et al). 1991;50:299-307 Kontula K (see Aalto-Setala et al). 1991;50:208-14
Hughes GS Jr, Ringer TV, Francom SF, Caswell KC, DeLoof Koopmans R, Dingemanse J, Danhof M, Horsten GPM, van
MJ, Spillers CR. Effects of fish oil and endorphins on the Boxtel CJ. The influence of dosage time of midazolam on
cold pressor test in hypertension. 1991;50:538-46 its pharmacokinetics and effects in humans. 1991;50:16-
Hughes JR (see Oliveto et al). 1991;50:157-64 24
Hulsman JARJ (see van Heiningen et al). 1991;50:410-9 Koren G (see Matsui et al). 1991;50:294-8
Humbert G, Brumpt I, Montay G, Le Liboux A, Frydman A, Koskinen P (see Aalto-Setala et al). 1991;50:208-14
Borsa-Lebas F, Moore N. Influence of rifampin on the Kosoglou T (see Burnier et al). 1991;50:181-91
phar macokinetics of pefloxacin. 1991;50:682-7 Koster RW, Cohen AF, Kluft C, Kasper FJ, van der Wouw
Hurwitz A, Vacek JL, Botteron GW, Sztern MI, Hughes EM, PA, Weatherley BC. The pharmacokinetics of recombi-
Jayaraj A. Mexiletine effects on theophylline disposition. nant double-chain t-PA (duteplase): effects of bolus injec-
1991;50:299-307 tion, infusions, and administration by weight in patients
Hutabarat RM, Unadkat JD, Kushmerick P, Aitken ML, Slatt- with myocardial infarction. 1991;50:267-77
ery JT, Smith AL. Disposition of drugs in cystic fibrosis. Kroon R (see van Steveninck et al). 1991;50:172-80
UI. Acetaminophen. 1991;50:695-701 Kubo SH (see Bank et al). 1991;50:314-21
Huttunen J (see Aalto-Setala et al). 1991;50:208-14 Kuhl DA (see Boucher et al). 1991;50:487-97
Hyslop NE Jr (see Lertora et al). 1991;50:442-9 Kushmerick P (see Hutabarat et al). 1991;50:695-701
Kyerematen GA, Morgan ML, Chattopadhyay B, deBethizy
I
JD, Vesell ES. Nicotine metabolism in humans.
Ittel TH (see Gladziwa et al). 1991;50:673-81 1991;50:463-4 (Letter reply)
J L
Jacob P III (see Benowitz and Jacob). 1991;50:462 (Letter) Lacour JT (see Lertora et al). 1991;50:442-9
(see Benowitz et al). 1991;50:286-93 Lambert GH. Effects of smoking on urinary metabolites.
Jacqz-Aigrain E (see Funck-Brentano et al). 1991;50:259-66 1991;50:464 (Letter)
Jaillon P (see Funck-Brentano et al). 1991;50:259-66 Lambert R (see Quérin et al). 1991:50:437-41
Jais JP (see Laplanche et al). 1991;50:39-54 Lant AF (see Noormohamed and Lant). 1991;50:564-72
Janisch L (see Ratain et al). 1991;50:573-9 Laplanche R, Fertil B, Niiesch E, Jais JP, Niederberger W,
Jann MW (see Grimsley et al). 1991;50:10-5 Steimer JL. Exploratory analysis of population phar maco-
Jayaraj A (see Hurwitz et al). 1991;50:299-307 kinetic data from clinical trials with application to isradip-
Jelliffe RW (see Dodge et al). 1991;50:25-31 ine. 1991;50:39-54
Jensen PK (see van Heiningen et al). 1991;50:410-9 Larochelle P (see Quérin et al). 1991;50:437-41
Johns DG (see Hartman et al). 1991;50:278-85 Lasagna L (see DiMasi et al). 1991;50:471-86 (Commentary)
Jones JK. A view from the drug utilization review manage- Laudignon N (see Bairam et al). 1991;50:32-8
ment organization sector. 1991;50:620-5 (Workshop) Leenhardt A (see Funck-Brentano et al). 1991;50:259-66
CLIN PHARMACOL THER
748 Author index
DECEMBER 1991
LeForce C (see Shepherd et al). 1991;50:338-49 Mueller BA (see Macias et al). 1991;50:688-94
Lehto P (see Neuvonen et al). 1991;50:498-502 Mutschler E (see Schulte et al). 1991;50:372-8
Leisure GA (see Bednarczyk et al). 1991;50:165-71 Muytjens HL (see Wymenga et al). 1991;50:215-20
Le Liboux A (see Humbert et al). 1991;50:682-7 N
Lertora JIL, Rege AB, Lacour JT, Ferencz N, George WJ,
VanDyke RB, Agrawal KC, Hyslop NE Jr. Phar- Nadzam DM (see Atkinson et al). 1991;50:125-8 (Commen-
tary)
makokinetics and long-term tolerance to mbavirin in
Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D,
asymptomatic patients infected with human immunodefici-
Sellers EM. Enalapril effects on alcohol intake and other
ency virus. 1991;50:442-9
Levey BA. Bridging the gender gap in research. 1991;50:641- consummatory behaviors in alcoholics. 1991;50:96-106
Nelson AD (see Bednarczyk et al). 1991;50:165-71
6 (Commentary)
Neugebauer G (see Martin et al). 1991;50:429-36
Lipton HL, Bird JA. Drug utilization review: state of the art
from an academic perspective. 1991;50:616-9 (Workshop) Neuvonen PJ, Kivisté KT, Lehto P. Interference of dairy prod-
ucts with the absorption of ciprofloxacin. 1991;50:498-502
Little D (see Bednarczyk et al). 1991;50:165-71
Ng SC (see Brandli et al). 1991;50:650-5
Lundahl J (see Soons et al). 1991;50:394-403
Niederberger W (see Laplanche et al). 1991;50:39-54
M Nierenberg DW, Disch M, Manheimer E, Patterson J, Ross J,
Mabadeje AFB, Akintonwa AA, Ashorobi RB. The value and Silvestri G, Summerhill E. Facilitating prompt diagnosis
effects of implementing an essential drugs list in the Lagos and treatment of the neuroleptic malignant syndrome.
University Teaching Hospital. 1991;50:121-4 (Commen- 1991;50:580-6
tary) Nitz M (see Bickel et al). 1991;50:420-8
Macias WL, Mueller BA, Scarim SK. Vancomycin pharmaco- Noormohamed FH, Lant AF. Muzolimine: renal site of action
kinetics in acute renal failure: preservation of nonrenal and interaction with probenecid in humans. 1991;50:564-
clearance. 1991;50:688-94 72
Macres M (see Halstenson et al). 1991;50:702-12 Novitch M. Drug utilization review in the 1990s.
Manfredi RL (see Vgontzas et al). 1991;50:730-7 1991;50:614-5 (Workshop)
Manheimer E (see Nierenberg et al). 1991;50:580-6 Niiesch E (see Laplanche et al). 1991;50:39-54
Manninen V (see Aalto-Setila et al). 1991;50:208-14 NussbergerJ (see Burnier et al). 1991;50:181-91
Manning DC, Raja SN, Meyer RA, Campbell JN. Pain and hy- oO
peralgesia after intradermal injection of bradykinin in hu-
Odlind B (see Tsao et al). 1991;50:713-20
mans. 1991;50:721-9
Olafsson A (see Fattinger et al). 1991;50:55-65
Manttari M (see Aalto-Setala et al). 1991;50:208-14 Oliveto AH, Hughes JR, Terry SY, Bickel WK, Higgins ST,
Marder H (see Giles et al). 1991;50:557-63
Pepper SL, Fenwick JW. Effects of caffeine on tobacco
Martin U, von MGllendorff E, Akpan W, Kientsch-Engel R,
withdrawal. 1991;50:157-64
Kaufmann B, Neugebauer G. Dose-ranging study of the
Olivieri N (see Matsui et al). 1991;50:294-8
novel recombinant plasminogen activator BM 06.022 in
Oosterhuis B (see van Heiningen et al). 1991;50:410-9
healthy volunteers. 1991;50:429-36
Osman OT, DeVane CL, Greenblatt DJ, Potter WZ. Pharma-
Matsui D, Klein J, Hermann C, Grunau V, McClelland R,
cokinetic and dynamic correlates of intravenous al-
Chung D, St-Louis P, Olivieri N, Koren G. Relationship
prazolam challenge. 1991;50:656-62
between the pharmacokinetics and iron excretion pharma-
O’Sullivan TA, Bauer LA, Horn JR, Zierler BK, Strandness
codynamics of the new oral iron chelator 1,2-dimethyl-3-
DE Jr, Williams-Warren J, Smith AL, Unadkat JD. Dispo-
hydroxypyrid4-one in patients with thalassemia.
sition of drugs in cystic fibrosis. II. Hepatic blood flow.
1991;50:294-8
1991;50:450-5
McCleery RA (see Dodge et al). 1991;50:25-31
McClelland R (see Matsui et al). 1991;50:294-8 P
Meyer RA (see Manning et al). 1991;50:721-9 Palm D (see Schulte et al). 1991;50:372-8
Meyer UA (see Gonzalez and Meyer). 1991;50:233-8 (Com- Panacek EA (see Bednarczyk et al). 1991;50:165-71
mentary) Pantuck CB (see Pantuck et al). 1991;50:254-8
Meyer WH (see Relling et al). 1991;50:308-13 Pantuck EJ, Pantuck CB, Kappas A, Conney AH, Anderson
Mick R (see Ratain et al). 1991;50:573-9 KE. Effects of protein and carbohydrate content of diet on
Mindel JS. Sports pharmacology? 1991;50:647-9 (Commen- drug conjugation. 1991;50:254-8
tary) Papageorgiou A (see Bairam et al). 1991;50:32-8
Miraldi FD (see Bednarczyk et al). 1991;50:165-71 Parbtani A (see Stern et al). 1991;50:66-70
Montay G (see Humbert et al). 1991;50:682-7 Park GD (see Shepherd et al). 1991;50:338-49
Mooij JMV (see van Baak et al). 1991;50:221-7 Patterson J (see Nierenberg et al). 1991;50:580-6
Moore A (see Kirkwood et al). 1991;50:404-9 Paulus HE (see Brandli et ai). 1991;50:650-5
Moore N (see Humbert et al). 1991;50:682-7 Pelonero A (see Kirkwood et al). 1991;50:404-9
Morgan ML (see Kyerematen et al). 1991;50:463-4 (Letter Pepper SL (see Oliveto et al). 1991;50:157-64
reply) Perret F (see Burnier et al). 1991;50:181-91
Morgan SL, Baggott JE, Refsum H, Ueland PM. Homocyste- Petros WP (see Relling et al). 1991;50:308-13
ine levels in patients with rheumatoid arthritis treated with Pieters MSM (see van Steveninck et al). 1991;50:172-80
low-dose methotrexate. 1991;50:547-56 Pijpers E (see Smits et al). 1991;50:529-37
VOLUME 50 Author index 749
NUMBER 6
Pitschner HF (see Schulte et al). 1991;50:372-8 Sambol NC, Sheiner LB. Dose-comparability of atenolol and
Pittman KA (see Shyu et al). 1991;50:503-7 betaxolol. 1991;50:350-1 (Letter reply)
Pluda JM (see Hartman et al). 1991;50:278-85 Sander GE (see Giles et al). 1991;50:557-63
Poirier JM (see Funck-Brentano et al). 1991;50:259-66 Sanhueza P (see Naranjo et al). 1991;50:96-106
Porchet M (see Burnier et al). 1991;50:181-91 Sarkissian E (see Brandli et al). 1991;50:650-5
Potter WZ (see Osman et al). 1991;50:656-62 Scarim SK (see Macias et al). 1991;50:688-94
Q Schachtel BP, Thoden WR, Konerman JP, Brown A, Chaing
DS. Headache pain model for assessing and comparing the
Quérin S, Lambert R, Cusson JR, Grégoire S, Vickers S,
efficacy of over-the-counter analgesic agents.
Stubbs J, Sweany AE, Larochelle P. Single-dose pharma-
1991;50:322-9
cokinetics of 4C-lovastatin in chronic renal failure.
Schaff RL (see Atkinson et al). 1991;50:125-8 (Commentary)
1991;50:437-41
Scheinbaum ML (see Weintraub et al). 1991;50:330-7
Quiroz AC (see Giles et al). 1991;50:557-63
Schell MJ (see Relling et al). 1991;50:308-13
R Schellens JHM, Ghabrial H, van der Wart HHF, Bakker EN,
Raistrick D (see Wolff et al). 1991;50:199-207 Wilkinson GR, Breimer DD. Differential effects of quini-
Raja SN (see Manning et al). 1991;50:721-9 dine on the disposition of nifedipine, sparteine, and
Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Wil- mephenytoin in humans. 1991;50:520-8
liams SF, Smiddy J. Paradoxical relationship between Schilsky RL (see Ratain et al). 1991;50:573-9
acetylator phenotype and amonafide toxicity. Schinnar R (see Strom et al). 1991;50:107-13
1991;50:573-9 Schnieders JR (see Halstenson et al). 1991;50:702-12
Rector TS (see Bank et al). 1991;50:314-21 Schoemaker HC (see Soons et al). 1991;50:394-403
Refsum H (see Morgan et al). 1991;50:547-56 (see van Steveninck et al). 1991;50:172-80
Rege AB (see Lertora et al). 1991;50:442-9 Schulke DG. A congressional perspective on inappropriate
Reidenberg JW. Understanding the publication process of drug therapy and drug utilization review. 1991;50:606-11
CLINICAL PHARMACOLOGY & THERAPEUTICS. (Workshop)
1991;50:357-62 (Commentary) Schulte B, Volz-Zang C, Mutschler E, Horne C, Palm D,
, Reidenberg MM. Report of a survey of some aspects of Wellstein A, Pitschner HF. AF-DX 116, a cardioselective
editorial board peer review at CLINICAL PHARMACOLOGY & muscarinic antagonist in humans: pharmacodynamic and
THERAPEUTICS. 1991;50:1-3 (Commentary) pharmacokinetic properties. 1991;50:372-8
Reidenberg MM. Effect of the requirement for triplicate pre- Sciberras D (see Warren et al). 1991;50:71-7
scriptions for benzodiazepines in New York State. Seiler KU (see Gladziwa et al). 1991;50:673-81
1991;50:129-31 (Commentary) Sellers EM (see Naranjo et al). 1991;50:96-106
(see Reidenberg and Reidenberg). 1991;50:1-3 (Com- Shaw M (see Strom et al). 1991;50:107-13
mentary) Sheiner LB. The intellectual health of clinical drug evaluation.
Reiss WG, Bauer LA, Horn JR, Zierler BK, Easterling TR, 1991;50:4-9 (Commentary)
Strandness DE Jr. The effects of oral nifedipine on hepatic (see Sambol and Sheiner). 1991;50:350-1 (Letter reply)
blood flow in humans. 1991;50:379-84 Shepherd AMM, LeForce C, Park GD, Hoop RS, Weir S. The
Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, determinants of response to diltiazem in hypertension.
Evans WE. Lower prevalence of the debrisoquin oxidative 1991;50:338-49
poor metabolizer phenotype in American black versus Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH.
white subjects. 1991;50:308-13 Food-induced reduction in bioavailability of didanosine.
(see Crom et al). 1991;50:132-40 1991;50:503-7
Rex J (see Bairam et al). 1991;50:32-8 Sieberth HG (see Gladziwa et al). 1991;50:673-81
Richardson CJ (see Dodge et al). 1991;50:25-31 Silvestri G (see Nierenberg et al). 1991;50:580-6
Richens A (see van Heiningen et al). 1991;50:410-9
Slattery JT (see Hutabarat et al). 1991;50:695-701
Ringer TV (see Hughes et al). 1991;50:538-46
Slooff TJJH (see Wymengs et al). 1991;50:215-20
Rivera GK (see Crom et al). 1991;50:132-40
Smiddy J (see Ratain et al). 1991;50:573-9
Robertson JT (see Boucher et al). 1991;50:487-97
Smith AL (see Hutabarat et al). 1991;50:695-701
Roffidal LE (see Giles et al). 1991;50:557-63
(see O’ Sullivan et al). 1991;50:450-5
Roosemalen MCM (see Soons et al). 1991;50:394-403
Smits P, Straatman C, Pijpers E, Thien T. Dose-dependent in-
Roots I (see Rost et al). 1991;50:141-9
hibition of the hemodynamic response to dipyridamole by
Ross J (see Nierenberg et al). 1991;50:580-6
caffeine. 1991;50:529-37
Rost KL, Brockméller J, Weber W, Roots I. Multiple-dose
Snodgrass WR (see Dodge et al). 1991;50:25-31
pharmacokinetics of ganglioside GM; after intravenous
Snyder ES (see Strom et al). 1991;50:107-13
and intramuscular administration to healthy volunteers.
Sobota JT (see Halstenson et al). 1991;50:702-12
1991;50:141-9
Soons PA, Vogels BAPM, Roosemalen MCM, Schoemaker
Roux A (see Funck-Brentano et al). 1991;50:259-66
HC, Uchida E, Edgar B, Lundahl J, Cohen AF, Breimer
Rubio A (see Weintraub et al). 1991;50:330-7
DD. Grapefruit juice and cimetidine inhibit stereoselective
Ryder D (see Brown et al). 1991;50:363-71
metabolism of nitrendipine in humans. 1991;50:394-403
s Spence JD (see Stern et al). 1991;50:66-70
St-Louis P (see Matsui et al). 1991;50:294-8 Spillers CR (see Hughes et al). 1991;50:538-46
CLIN PHARMACOL THER
750 Author index DECEMBER 1991
Steimer JL (see Laplanche et al). 1991;50:39-54 analog lines to the effects of incremental doses of tem-
Stern RH, Spence JD, Freeman DJ, Parbtani A. Tolerance to azepam in healthy volunteers. 1991;50:172-80
nicotinic acid flushing. 1991;50:66-70 Vesell ES. The model drug approach in clinical phar macoi-
Stewart CF, Arbuck SG, Fleming RA, Evans WE. Relation of ogy. 1991;50:239-48 (Commentary)
systemic exposure to unbound etoposide and hematologic (see Kyerematen et al). 1991;50:463-4 (Letter reply)
toxicity. 1991;50:385-93 Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL.
Stewart PE. A message from the finance committee chairper- Effects of lovastatin and pravastatin on sleep efficiency and
son. 1991;50:587 sleep stages. 1991;50:730-7
Straatman C (see Smits et al). 1991;50:529-37 Vickers S (see Quérin et al). 1991;50:437-41
Strandness DE Jr (see O’Sullivan et al). 1991;50:450-5 VicekJ (see Fattinger et al). 1991;50:55-65
(see Reiss et al). 1991;50:379-84 Vogels BAPM (see Soons et al). 1991;50:394-403
Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M, Volz-Zang C (see Schulte et al). 1991;50:372-8
Waiter SL. No causal relationship between transdermal von Mollendorff E (see Martin et al). 1991;50:429-36
scopolamine and seizures: methodologic lessons for phar- Vozeh S (see Fattinger et al). 1991;50:55-65
macoepidemiology. 1991;50:107-13 W
Stubbs J (see Quérin et al). 1991;50:437-41
Waeber B (see Burnier et al). 1991;50:181-91
Summerhill E (see Nierenberg et al). 1991;50:580-6
Waiter SL (see Strom et al). 1991;50:107-13
Sweany AE (see Quérin et al). 1991;50:437-41
Sztern MI (see Hurwitz et al). 1991;50:299-307
ment of MK-467, a peripheral 02-adrenergic receptor an-
Szumlanski C (see Guerciolini et al). 1991;50:663-72
tagonist, with intravenous clonidine. 1991;50:71-7
ar Watanabe M (see Halstenson et al). 1991;50:702-12
Tan FS (see van Baak et al). 1991;50:221-7 Weatherley BC (see Koster et al). 1991;50:267-77
(see Kalow and Tang). 1991;50:465 (Letter reply) Weber W (see Bickel et al). 1991;50:420-8
Tang BK (see Kalow and Tang). 1991;50:508-19 (see Rost et al). 1991;50:141-9
Terry SY (see Oliveto et al). 1991;50:157-64 Weinshilboum RM (see Guerciolini et al). 1991;50:663-72
Theeuwes A (see Wymenga et al). 1991;50:215-20 Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML.
Thien T (see Smits et al). 1991;50:529-37 Sibutramine in weight control: a dose-ranging, efficacy
Thoden WR (see Schachtel et al). 1991;50:322-9 study. 1991;50:330-7
Thomas RV (see Hartman et al). 1991;50:278-85 Weir S (see Shepherd et al). 1991;50:338-49
Thomsen T (see Bickel et al). 1991;50:420-8 Wellstein A (see Schulte et al). 1991;50:372-8
Tsao C, Greene P, Odlind B, Brater DC. Pharmacokinetics of Wenk M (see Fattinger et al). 1991;50:55-65
recombinant human superoxide dismutase in healthy vol- Wijnen JAG (see van Baak et al). 1991;50:221-7
unteers. 1991;50:713-20 Wilkinson GR (see Schellens et al). 1991;50:520-8
Tyson KL (see Vgontzas et al). 1991;50:730-7 Williams RE (see Bank et al). 1991;50:314-21
U Williams SF (see Ratain et al). 1991;50:573-9
Williams-WarrtenJ (see O'Sullivan et al). 1991;50:450-5
Uchida E (see Soons et al). 1991;50:394-403 Wolff K, Hay A, Raistrick D, Calvert R, Feely M. Measuring
Ueland PM (see Morgan et al). 1991;50:547-56 compliance in methadone maintenance patients: use of a
Unadkat JD (see Hutabarat et al). 1991;50:695-701
pharmacologic indicator to "estimate" methadone plasma
(see O’Sullivan et al). 1991;50:450-5
levels. 1991;50:199-207
Vv Wood AJJ (see Zhou and Wood). 1991;50:150-6
Vacek JL (see Hurwitz et al). 1991;50:299-307 Woodley-Remus D (see Naranjo et al). 1991;50:96-106
van Baak MA, Mooij JMV, Wijnen JAG, Tan FS. Submaxi- Wymenga AB, Hekster YA, Theeuwes A, Muytjens HL, van
mal endurance exercise perfor mance during enalapril treat- Horn JR, Slooff TJJH. Antibiotic use after cefuroxime pro-
ment in_ patients with essential hypertension. phylaxis in hip and knee joint replacement. 1991;50:215-
1991;50:221-7 20
van Boxtel CJ (see Koopmans et al). 1991;50: 16-24 Wyvill KM (see Hartman et al). 1991;50:278-85
van der Wart HHF (see Schellens et al). 1991;50:520-8 -
van der Wouw PA (see Koster et al). 1991;50:267-77
Yarchoan R (see Hartman et al). 1991;50:278-85
VanDyke RB (see Lertora et al). 1991;50:442-9
van Heiningen PNM, Eve MD, Oosterhuis B, Jonkman JHG, Z
de Bruin H, Hulsman JARJ, Richens A, Jensen PK. The in- Zawistowich L. What the government wants. 1991;50:603-5
fluence of age on the pharmacokinetics of the antiepileptic (Workshop)
oxcarbazepine. 1991;50:410-9 Zhou HH, Wood AJJ. Increased suppression of exercise-in-
van Horn JR (see Wymenga et al). 1991;50:215-20 duced increase in renin by propranolol in Chinese subjects.
van Steveninck AL, Schoemaker HC, Pieters MSM, Kroon R, 1991;50:150-6
Breimer DD, Cohen AF. A comparison of the sensitivities Zierler BK (see O’Sullivan et al). 1991;50:450-5
of adaptive tracking, eye movement analysis, and visual (see Reiss et al). 1991;50:379-84
Subject index
A Alprazolam
Acetaminophen Influence of menstrual cycle and gender on alprazolam pharmaco-
Disposition of drugs in cystic fibrosis. II]. Acetaminophen kinetics (Kirkwood et al). 1991;50:404-9
(Hutabarat et al). 1991;50:695-701 Pharmacokinetic and dynamic correlates of intravenous al-
Effects of protein and carbohydrate content of diet on drug conju- prazolam challenge (Osman et al). 1991;50:656-62
gation (Pantuck et al). 1991;50:254-8 American Medical Association
Acetylation Submissions by meeting participants (Abrams). 1991;50:639-40
Paradoxical relationship between acetylator phenotype and (Workshop)
amonafide toxicity (Ratain et al). 1991;50:573-9 American Society for Clinical Pharmacology and
Acupuncture points Therapeutics
Local anesthesia blocks the antiemetic action of P6 acupuncture Contributor acknowledgement. 1991;50:467
(Dundee and Ghaly). 1991;50:78-80 Future meeting dates and sites. 1991;50:227
Acute renal failure; see Kidney failure, acute A message from the finance committee chairperson (Stewart).
Adapalene 1991;50:587
Adapalene (USAN List No. 333). 1991;50:588 A message from the president (Abernethy). 1991;50:114
Administration, cutaneous A message from the president—come to Orlando, March 18-20,
No causal relationship between transdermal scopolamine and sei- 1992 (Abernethy). 1991;50:738
zures: methodologic lessons for pharmacoepidemiology Nominations for awards. 1991;50:352-3
(Strom et al). 1991;50:107-13 A note from the Scientific Program Committee chairperson: sub-
Stable isotope method for studying transdermal drug absorption: mission of abstracts for the 1992 annual meeting (Data).
the nicotine patch (Benowitz et al). 1991;50:286-93 1991;50:115
Administratioonra,l Amifostine
The effects of oral nifedipine on hepatic blood flow in humans Amifostine (USAN List No. 332). 1991;50:468
(Reiss et al). 1991;50:379-84 Amiodarone
Pharmacokinetics of 2’,3’-dideoxyinosine in patients with severe
human immunodeficiency infection. II. The effects of different Influence of amiodarone on genetically determined drug metabo-
oral formulations and the presence of other medications (Hart- lism in humans (Funck-Brentano et al). 1991;50:259-66
man et al). 1991;50:278-85 Amonafide
Adrenergic alpha receptor agonists Paradoxical relationship between acetylator phenotype and
Assessment of MK-467, a peripheral 2-adrenergic receptor an- amonafide toxicity (Ratain et al). 1991;50:573-9
tagonist, with intravenous clonidine (Warren et al). Analgesics
1991;50:71-7 Headache pain model for assessing and comparing the efficacy of
Responsiveness of peripheral veins to vasodilators and the effect over-the-counter analgesic agents (Schachtel et al).
of nifedipine on a-adrenergic responsiveness in hypertension 1991;50:322-9
(Ford et al). 1991;50:192-8 Anesthesia, local
Adrenergic beta receptor blockaders Local anesthesia blocks the antiemetic action of P6 acupuncture
Increased suppression of exercise-induced increase in renin by (Dundee and Ghaly). 1991;50:78-80
propranolol in Chinese subjects (Zhou and Wood). Angiotensin-converting enzyme inhibitors
1991;50:150-6
Submaximal endurance exercise performance during enalapril
AF-DX 116
treatment in patients with essential hypertension (van Baak et
AF-DX 116, a cardioselective muscarinic antagonist in humans: al). 1991;50:221-7
pharmacodynamic and pharmacokinetic properties (Schulte et
Antibiotics
al). 1991;50:372-8
Age factors Antibiotic use after cefuroxime prophylaxis in hip and knee joint
The influence of age on the pharmacokinetics of the antiepileptic replacement (Wymenga et al). 1991;50:215-20
oxcarbazepine (van Heiningen et al). 1991;50:410-9 Influence of rifampin on the pharmacokinetics of pefloxacin
AI/CIII genes (Humbert et al). 1991;50:682-7
DNA polymorphisms of apolipoprotein B and AI/CIII genes and Anticonvulsants
response to gemfibrozil treatment (Aalto-Setala et al). The influence of age on the pharmacokinetics of the antiepileptic
1991;50:208-14 oxcarbazepine (van Heiningen et al). 1991;50:410-9
Alcoholism Antiemetics
Enalapril effects on alcohol intake and other consummatory be- Local anesthesia blocks the antiemetic action of P6 acupuncture
haviors in alcoholics (Naranjo et al). 1991;50:96-106 (Dundee and Ghaly). 1991;50:78-80
Algorithms Antiepileptic agents; see Anticonvulsants
Gentamicin population pharmacokinetic models for low birth Antihypertensive agents
weight infants using a new nonparametric method (Dodge et The determinants of response to diltiazem in hypertension (Shep-
al). 1991;50:25-31 herd et al). 1991;50:338-49
Alpha adrenergic agonists; see Adrenergic alpha receptor
Antihypertensives
agonists
The determinants of response to diltiazem in hypertension (Shep-
herd et al). 1991;50:338-49
Antineoplastic agents
*July, pp. 1-120; August, pp. 121-232; September, pp. 233-356; October, pp.
Paradoxical relationship between acetylator phenotype and
357-470; November (Part 1), pp. 471-592; November (Part 2), pp. 593-640; De-
cember, pp. 641-760 amonafide toxicity (Ratain et al). 1991;50:573-9
751
CLIN PHARMACOL THER
752 Subject index DECEMBER 1991
Antipyrine in healthy subjects by means of positron emission tomography
Age-related differences in hepatic drug clearance in children: stud- (Bednarczyk et al). 1991;50:165-71
ies with lorazepam and antipyrine (Crom et al). 1991;50:132- Bretazenil
40 Bretazenil (USAN List No. 329). 1991;50:118
Effect of neurotrauma on hepatic drug clearance (Boucher et al). Brimonidine tartrate
1991;50:487-97 Brimonidine tartrate (USAN List No. 334). 1991;50:740
Apolipoproteins
DNA polymorphisms of apolipoprotein B and AI/CIII genes and Cc
response to gemfibrozil treatment (Aalto-Setala et al).
1991;50:208-14
14C lovastatin; see Lovastatin
Arthritis
Caffeine
Individual variability in concentrations of urinary sulindac sulfide
(Brandli et al). 1991;50:650-5 Dose-dependent inhibition of the hemodynamic response to dipyr-
Arthritis, rheumatoid idamole by caffeine (Smits et al). 1991;50:529-37
Homocysteine levels in patients with rheumatoid arthritis treated Effects of caffeine on tobacco withdrawal (Oliveto et al).
1991;50:157-64
with low-dose methotrexate (Morgan et al). 1991;50:547-56
Aspirin Paradoxical relationship between acetylator phenotype and
amonafide toxicity (Ratain et al). 1991;50:573-9
Bridging the gender gap in research (Levey). 1991;50:641-6
A pharmacodynamic interaction between caffeine and
(Commentary)
phenylpropanolamine (Brown et al). 1991;50:363-71
Atrial natriuretic factors; see Natriuretic peptides, atrial
Use of caffeine metabolite ratios to explore CYP1A2 and xanthine
B oxidase activities (Kalow and Tang). 1991;50:508-19
Bar mastine Calcium antagonists; see Calcium channel blockers
Calcium channel blockers
Barmastine (USAN List No. 333). 1991;50:588
Batelapine maleate The determinants of response to diltiazem in hypertension (Shep-
Batelapine maleate (USAN List No. 329). 1991;50:119 herd et al). 1991;50:338-49
Exploratory analysis of population pharmacokinetic data from
Bemesetron
clinical trials with application to isradipine (Laplanche et al).
Bemesetron (USAN List No. 334). 1991;50:741
1991;50:39-54
Benzodiazepines
Carbamazepine
Effect of the requirement for triplicate prescriptions for
Cocaine reduction in unmotivated crack users using carbamazep-
benzodiazepines in New York State (Reidenberg).
ine versus placebo in a short-term, double-blind crossover de-
1991;50:129-31 (Commentary)
sign (Halikas et al). 1991;50:81-95
Beraprost
Increased carbamazepine plasma concentrations after fluoxetine
Beraprost (USAN List No. 333). 1991;50:590
coadministration (Grimsley et al). 1991;50:10-5
Beraprost sodium Carbohydrates
Beraprost sodium (USAN List No. 333). 1991;50:591 Effects of protein and carbohydrate content of diet on drug conju-
Beta adrenergic blockers; see Adrenergic beta receptor
gation (Pantuck et al). 1991;50:254-8
blockaders Cefdinir
Binospirone mesylate Cefdinir (USAN List No. 334). 1991;50:740
Binospirone mesylate (USAN List No. 330). 1991;50:230 Cefprozil
Bioavailability; see Biological availability Cefprozil (USAN List No. 329). 1991;50:117
Biological availability Cefuroxime
Food-induced reduction in bioavailability of didanosine (Shyu et Antibiotic use after cefuroxime prophylaxis in hip and knee joint
al). 1991;50:503-7 replacement (Wymenga et al). 1991;50:215-20
Blacks Cerebral blood flow; see Brain, blood supply
Lower prevalence of the debrisoquin oxidative poor metabolizer Ceronapril
phenotype in American black versus white subjects (Relling et
Ceronapril (USAN No. 329). 1991;50:118
al). 1991;50:308-13
Blood Chinese; see Mongoloid race
Cholinergic receptors; see Receptors, cholinergic
Relation of systemic exposure to unbound etoposide and hemato-
logic toxicity (Stewart et al). 1991;50:385-93 Cholinesterase inhibitors
Blood flow, regional; see Regional blood flow Pharmacokinetics of galanthamine in humans and corresponding
BM 06.022 cholinesterase inhibition (Bickel et al). 1991;50:420-8
Dose-ranging study of the novel recombinant plasminogen activa- Chronic renal failure; see Kidney failure, chronic
tor BM 06.022 in healthy volunteers (Martin et al). Cimetidine
1991;50:429-36 Grapefruit juice and cimetidine inhibit stereoselective metabolism
Books received of nitrendipine in humans (Soons et al). 1991;50:394-403
Books received. 1991;50:356 Ciprofloxacin
Bradycardia Comparison of the effect of temafloxacin, ciprofloxacin, or pla-
AF-DX 116, a cardioselective muscarinic antagonist in humans: cebo on cerebral blood flow, glucose, and oxygen metabolism
pharmacodynamic and pharmacokinetic properties (Schulte et in healthy subjects by means of positron emission tomography
al). 1991;50:372-8 (Bednarczyk et al). 1991;50:165-71
Bradykinin Ciprofloxin
Pain and hyperalgesia after intradermal injection of bradykinin in Interference of dairy products with the absorption of ciprofloxacin
humans (Manning et al). 1991;50:721-9 (Neuvonen et al). 1991;50:498-502
Brain, blood supply Circadian rhythm
Comparison of the effect of temafloxacin, ciprofloxacin, or pla- The influence of dosage time of midazolam on its pharmacokinet-
cebo on cerebral blood flow, glucose, and oxygen metabolism ics and effects in humans (Koopmans et al). 1991;50:16-24